drugset / Trial / NCT03097588
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
Phase 2
Completed
43 enrolled
OHSU Knight Cancer Institute
Helsinn Therapeutics (U.S.), Inc · collabOregon Health and Science University · collab
NaSingle-groupOpen-labelSupportive care
Summary
This phase II trial studies how well netupitant and palonosetron hydrochloride work in preventing chemotherapy induced nausea and vomiting in patients with cancer undergoing BEAM conditioning regimen before stem cell transplant. Chemotherapy, such as carmustine, cytarabine, etoposide, and melphalan (BEAM), makes people feel sick to their stomach and causes vomiting. Netupitant and palonosetron hydrochloride may reduce the nausea and vomiting caused by the BEAM treatment.
Timeline
- Start
- 2017-04-27
- Primary completion
- 2020-02-20
- Completion
- 2020-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Netupitant | Small molecule | 300 mg | Oral |
| Subject | Palonosetron | Other / unclassified | 0.5 mg | Oral |